Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system.
T-Track ImmunoScan detects cell mediated immune functions through the measurement of interferon gamma (IFNg) in combination with an in-house developed ELISpot readout
T-Track ImmunoScan and the T-activated ImmunoScan Cocktail are available for research use only to monitoring host response markers including specific recall responses in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation. Based on the proven, sensitive and accurate T-Track platform technology, T-Track ImmunoScan detects cell mediated immune functions through the measurement of interferon gamma (IFNg) in combination with an in-house developed ELISpot readout.
Lophius also offers the T-activated ImmunoScan Cocktail as a mixture of stimulants outside of its IFNg ELISpot kit format for use in combination with Lophius’ highly standardized and ultrasensitive T-Track basic ELISpot kits to measure other cytokines such as IL-2, IL-4, IL-6, IL-10, granzyme B and others coming soon. Furthermore, e.g. in case where tailoring of the cytokine or chemokine panel to specific cell types is important, scientists may use T-activated ImmunoScan Cocktail also in other readout formats such as flow cytometry.
Both T-Track ImmunoScan and the T-activated ImmunoScan Cocktail are intended to be typically used in solid organ or bone marrow transplant recipients to measure the level of a change in immunosuppression with the ultimate goal to tailor immunosuppressive treatments to avoid both transplant rejection and infection with /reactivation of pathogens such as CMV, EBV, BKV, ADV or aspergillus. Other indications to assessing the patients’ functional immune status are rheumatic disorders, Inflammatory Bowel Disease, Cancer, HIV, and other immunosuppressive conditions.
“We are very excited to further expand our diagnostic T-Track product line by adding T-Track ImmunoScan and to offer the T-activated ImmunoScan Cocktail for applications other than our IFNg ELISpot. Both products have the potential to significantly improve the standard of diagnosis and ultimately treatment of diseases associated with immunosuppression and emphasizes Lophius’ commitment to its goal of making truly personalized medicine broadly available in various indications,” said Dr. Robert Phelps, CEO of Lophius Biosciences.
Lophius Biosciences
www.lophius.com
